Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
EJ Jabbour, JE Cortes, HM Kantarjian - Clinical Lymphoma Myeloma and …, 2013 - Elsevier
The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …
Membrane proteins: the key players of a cancer cell
KR Kampen - The Journal of membrane biology, 2011 - Springer
Membrane proteins are involved in the prognosis of the most common forms of cancer.
Membrane proteins are the hallmark of a cancer cell. The overexpressed membrane …
Membrane proteins are the hallmark of a cancer cell. The overexpressed membrane …
Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy
Chronic myeloid leukemia (CML), which is characterized by the Philadelphia translocation,
which fuses breakpoint cluster region (BCR) sequences from chromosome 22 upstream of …
which fuses breakpoint cluster region (BCR) sequences from chromosome 22 upstream of …
Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted
therapies designed to inhibit the tyrosine kinase activity of the BCR‐ABL oncoprotein have …
therapies designed to inhibit the tyrosine kinase activity of the BCR‐ABL oncoprotein have …
[HTML][HTML] Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells
Tyrosine kinase inhibitor (TKI) resistance is a major problem in chronic myeloid leukemia
(CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective …
(CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective …
[图书][B] A guide to outcome modeling in radiotherapy and oncology: listening to the data
I El Naqa - 2018 - books.google.com
This book explores outcome modeling in cancer from a data-centric perspective to enable a
better understanding of complex treatment response, to guide the design of advanced …
better understanding of complex treatment response, to guide the design of advanced …
[PDF][PDF] Chronic myeloid leukemia-prognostic value of mutations
B Kaleem, S Shahab, N Ahmed… - Asian Pac J Cancer Prev, 2015 - academia.edu
Chronic myeloid leukemia (CML) is a stem cell disorder characterized by unrestricted
proliferation of the myeloid series that occurs due to the BCR-ABL fusion oncogene as a …
proliferation of the myeloid series that occurs due to the BCR-ABL fusion oncogene as a …
[HTML][HTML] Integrating single-cell transcriptome and network analysis to characterize the therapeutic response of chronic myeloid Leukemia
J Ma, N Pettit, J Talburt, S Wang, SM Weissman… - International Journal of …, 2022 - mdpi.com
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by a unique
BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) were developed to target the BCR …
BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKIs) were developed to target the BCR …
Why imatinib remains an exception of cancer research
SD Horne, JB Stevens, BY Abdallah… - Journal of Cellular …, 2013 - Wiley Online Library
The archetype driving the drug targeting approach to cancer therapy is the success of
imatinib against chronic phase chronic myeloid leukemia (CML‐CP). Molecular targeting …
imatinib against chronic phase chronic myeloid leukemia (CML‐CP). Molecular targeting …
[HTML][HTML] Progress in RNAi-mediated molecular therapy of acute and chronic myeloid leukemia
B Landry, J Valencia-Serna, H Gul-Uludag… - … Therapy-Nucleic Acids, 2015 - cell.com
Leukemias arise from genetic alterations in normal hematopoietic stem or progenitor cells,
leading to impaired regulation of proliferation, differentiation, apoptosis, and survival of the …
leading to impaired regulation of proliferation, differentiation, apoptosis, and survival of the …